tag:blogger.com,1999:blog-6936739316605533122024-03-13T22:49:20.971+01:00InteressenkonflikteDeutsches Netzwerk Evidenzbasierte Medizin e. V.EbM-Netzwerkhttp://www.blogger.com/profile/09908033891364783614noreply@blogger.comBlogger52125tag:blogger.com,1999:blog-693673931660553312.post-17792940978226756142012-03-14T13:59:00.001+01:002012-03-14T13:59:51.256+01:00Offenlegung von Interessenkonflikten - unerwünschte Wirkungen möglichLoewenstein G, Sah S, Cain DM.<br />
The Unintended Consequences of Conflict
of Interest Disclosure.<br />
JAMA: The Journal of the American Medical
Association 2012;307:669-70 <a href="http://jama.ama-assn.org/content/307/7/669.short">Abstract</a><br />
<br />
Beitrag im Forum Gesundheitspolitik <a href="http://forum-gesundheitspolitik.de/artikel/artikel.pl?artikel=2085">Link</a>Klempererhttp://www.blogger.com/profile/16734777579980886077noreply@blogger.com0tag:blogger.com,1999:blog-693673931660553312.post-29294039239692367132012-02-29T20:43:00.002+01:002012-02-29T20:43:27.752+01:00Avastin bei metastasiertem Brustkrebs - Zulassungsbehörden entscheiden gegensätzlich<div style="font-family: "Helvetica Neue",Arial,Helvetica,sans-serif;">
Identische Datenlage - entgegengesetzte Entscheidungen. </div>
<div style="font-family: "Helvetica Neue",Arial,Helvetica,sans-serif;">
Dazu ein Beitrag im Forum Gesundheitspolitik <a href="http://forum-gesundheitspolitik.de/artikel/artikel.pl?artikel=2058%20">Link</a></div>
<div style="font-family: "Helvetica Neue",Arial,Helvetica,sans-serif;">
<br /></div>
<div style="font-family: "Helvetica Neue",Arial,Helvetica,sans-serif;">
Die amerikanische Zulassungsbehörde FDA hat ein transparentes Verfahren von Anhörung und Entscheidung. Die Anhörunegn stehen als Video und als Transkript (28./29.6.2011: 581 Seiten) Verfügung <a href="http://www.fda.gov/NewsEvents/MeetingsConferencesWorkshops/ucm255874.htm">Link</a></div>
<div style="font-family: "Helvetica Neue",Arial,Helvetica,sans-serif;">
<br /></div>
<div style="font-family: "Helvetica Neue",Arial,Helvetica,sans-serif;">
Die Europäische Zulassungsbehörde EMA lässt sich hingegen bei ihrer Entscheidung nicht in die Karten schauen.nicht.</div>
<div style="direction: ltr; font-family: "Helvetica Neue",Arial,Helvetica,sans-serif; margin-bottom: 0pt; margin-left: 0in; margin-top: 4.8pt; text-align: left; text-indent: 0in; unicode-bidi: embed; vertical-align: baseline;">
6 der 12 Mitglieder der <span style="color: black; font-size: small;"><a href="http://www.blogger.com/goog_1798012988">Scientific Advisory Group on </a><a href="http://www.ema.europa.eu/ema/index.jsp?curl=pages/contacts/CHMP/people_listing_000031">Oncology </a>der EMA haben Interessenkonflikte.</span></div>
<div style="direction: ltr; margin-bottom: 0pt; margin-left: 0in; margin-top: 4.8pt; text-align: left; text-indent: 0in; unicode-bidi: embed; vertical-align: baseline;">
<span style="color: black; font-size: small;"><span style="font-family: Arial;"><span style="font-family: "Helvetica Neue",Arial,Helvetica,sans-serif;">In der Sendung von Monitor am 1.3. um 21 Uhr im ARD wird dieses Thema aufgegriffen. </span><a href="http://www.ardmediathek.de/ard/servlet/content/3517136?documentId=9654632" style="font-family: "Helvetica Neue",Arial,Helvetica,sans-serif;">Link</a></span></span></div>Klempererhttp://www.blogger.com/profile/16734777579980886077noreply@blogger.com0tag:blogger.com,1999:blog-693673931660553312.post-38420069983429908822012-02-16T21:45:00.003+01:002012-02-16T21:45:52.396+01:00Ethics Manual des American College of PhysiciansBeitrag im Forum Gesundheotspolitik <a href="http://forum-gesundheitspolitik.de/artikel/artikel.pl?artikel=2056">Link</a>Klempererhttp://www.blogger.com/profile/16734777579980886077noreply@blogger.com0tag:blogger.com,1999:blog-693673931660553312.post-46561179435432536012012-02-16T21:43:00.002+01:002012-02-16T21:43:59.894+01:00"Tamiflu III": Warum ein Review auf Daten von 68% der durchgeführten Studien zum Grippe-Blockbuster verzichten muss?Beitrag im Forum Gesundheitspolitik <a href="http://forum-gesundheitspolitik.de/artikel/artikel.pl?artikel=2064">Link</a>Klempererhttp://www.blogger.com/profile/16734777579980886077noreply@blogger.com0tag:blogger.com,1999:blog-693673931660553312.post-5409792992064994512012-02-16T21:41:00.003+01:002012-02-16T21:41:20.568+01:00Es werde Licht - Transparenzregelungen in den USA werden konkretisiertBeitrag im Forum Gesundheitspolitik <a href="http://forum-gesundheitspolitik.de/artikel/artikel.pl?artikel=2082">Link</a>Klempererhttp://www.blogger.com/profile/16734777579980886077noreply@blogger.com0tag:blogger.com,1999:blog-693673931660553312.post-6351009808990564712012-02-16T21:39:00.001+01:002012-02-16T21:39:09.023+01:00Seelsorge für die Industrie. SPIEGEL 16.5.2011<h2 style="font-weight: normal;">
Seelsorge für die Industrie</h2>
<div class="spAuthor">
Von Jörg Blech</div>
<div class="spAuthor">
<br /></div>
<span style="font-size: small;"><strong>Die Elite der Nervenheilkunde ist eng mit
Pharmakonzernen verflochten: Psychiater, Neurologen, aber auch
Psychologen arbeiten als bezahlte Berater für die Unternehmen. Nun
fordert ein Professor seine Kollegen auf, ihre Nebeneinkünfte
offenzulegen.</strong></span><br />
<br />
<a href="http://www.spiegel.de/spiegel/print/d-78522323.html">Link </a><br />
<br />
(versehentlich im Mai nicht veröffentlicht, aber immer noch lesenswert)Klempererhttp://www.blogger.com/profile/16734777579980886077noreply@blogger.com0tag:blogger.com,1999:blog-693673931660553312.post-79808791439562702892012-02-16T21:35:00.001+01:002012-02-16T21:39:58.476+01:00Being the Ghost in the Machine: A Medical Ghostwriter's Personal ViewPLoS 9.8.2011<br />
<br />
<br />
<a href="http://www.plosmedicine.org/article/info%3Adoi%2F10.1371%2Fjournal.pmed.1001071">Link</a><br />
<br />
Introduction Top<br />
Ethical concerns about medical ghostwriting have been directed primarily at “guest” authors and the pharmaceutical companies that pay them. One voice that is largely missing is that of the ghostwriters themselves who, after all, create the documents that are in the ethical and legal crosshairs. Without them, one could argue, there can be no fraud, because it is they who create the fraudulent product.<br />
<br />
For almost 11 years, I worked as a medical writer, creating a variety of pieces including the occasional ghostwritten article. For the most part, I never saw the finished paper, nor did I care to. This article describes what I did, why I did it, why I stopped doing it, and what I think might be done about the problem of fraud in authorship.<br />
<br />
(versehentlich im August nicht veröffentlicht, aber immer noch lesenswert)<br />
<br />Klempererhttp://www.blogger.com/profile/16734777579980886077noreply@blogger.com0tag:blogger.com,1999:blog-693673931660553312.post-7481727379177491992011-10-13T20:02:00.000+02:002011-10-13T20:02:49.046+02:00Leitlinien zu Diabetes und Cholesterin: 52% der Autoren mit InteressenkonfliktenNeuman J, Korenstein D, Ross JS, Keyhani S. Prevalence of financial conflicts of interest among panel members producing clinical practice guidelines in Canada and United States: cross sectional study. BMJ 2011;343.Volltext <a href="http://www.bmj.com/content/343/bmj.d5621.full.pdf">Link</a><br />
Beitrag im Forum Gesundheitspolitik <a href="http://forum-gesundheitspolitik.de/artikel/artikel.pl?artikel=2013">Link</a>Klempererhttp://www.blogger.com/profile/16734777579980886077noreply@blogger.com0tag:blogger.com,1999:blog-693673931660553312.post-78690813919655975112011-09-03T15:50:00.002+02:002011-09-03T15:53:24.917+02:00PLoS Medicine. Beiträge zu Ghost Writing, Aug. 2011Gegen ghost writing. Die Herkunft von Studien offen legen - schwierig aber notwendig
<br />in <a href="http://forum-gesundheitspolitik.de/artikel/artikel.pl?artikel=1997">Forum Gesundheitspolitik </a>Klempererhttp://www.blogger.com/profile/16734777579980886077noreply@blogger.com0tag:blogger.com,1999:blog-693673931660553312.post-12607223532312025672011-08-10T19:11:00.001+02:002011-08-10T19:12:47.599+02:00Being the Ghost in the Machine: A Medical Ghostwriter's Personal ViewPLoS 9.8.2011
<br />
<br />
<br /><a href="http://www.plosmedicine.org/article/info%3Adoi%2F10.1371%2Fjournal.pmed.1001071">Link</a>
<br />
<br />Introduction
<br />Ethical concerns about medical ghostwriting have been directed primarily at “guest” authors and the pharmaceutical companies that pay them. One voice that is largely missing is that of the ghostwriters themselves who, after all, create the documents that are in the ethical and legal crosshairs. Without them, one could argue, there can be no fraud, because it is they who create the fraudulent product.
<br />
<br />For almost 11 years, I worked as a medical writer, creating a variety of pieces including the occasional ghostwritten article. For the most part, I never saw the finished paper, nor did I care to. This article describes what I did, why I did it, why I stopped doing it, and what I think might be done about the problem of fraud in authorship.Klempererhttp://www.blogger.com/profile/16734777579980886077noreply@blogger.com0tag:blogger.com,1999:blog-693673931660553312.post-79225741869213338122011-08-10T19:05:00.002+02:002011-08-10T19:08:12.113+02:00How Industry Uses the ICMJE Guidelines to Manipulate Authorship—And How They Should Be RevisedPLoS 9. August 2011
<br />
<br /><a href="http://www.plosmedicine.org/article/info%3Adoi%2F10.1371%2Fjournal.pmed.1001072">Link</a>
<br />
<br />Summary Points
<br />Academic authorship boosts the credibility of industry publications and masks their commercial function.
<br />Alongside traditional “guest authorship” and ghostwriting, industry may simply exaggerate the contribution of named academic authors and downplay that of commercial writers, who are excluded from authorship but listed as contributors in the small print.
<br />Rather than obstructing industry, the current International Committee of Medical Journal Editors (ICMJE) authorship guidelines provide a ready tool for misattributing authorship. Industry also relies on selective interpretations of key authorship concepts.
<br />The ICMJE guidelines should be fundamentally revised and the concept of origination given comparable importance to authorship and contributorship.
<br />Companies and writers who work on industry publications should be listed as byline authors.Klempererhttp://www.blogger.com/profile/16734777579980886077noreply@blogger.com0tag:blogger.com,1999:blog-693673931660553312.post-86989860009531339312011-05-16T20:34:00.000+02:002011-05-16T20:35:53.455+02:00Pillentrick des Pharmalobbyismus. Wie man Patienten um den Finger wickeltFinancial Times Deutschland 14.5.2011<br /><a href="http://www.ftd.de/unternehmen/:pillentrick-des-pharmalobbyismus-wie-man-patienten-um-den-finger-wickelt/60050201.html?mode=print#">Link</a>Klempererhttp://www.blogger.com/profile/16734777579980886077noreply@blogger.com0tag:blogger.com,1999:blog-693673931660553312.post-67302166639496057282011-05-16T19:39:00.000+02:002011-05-16T19:40:51.804+02:00Cardiac Society Draws Bulk of Funding From Stent Makersby Charles Ornstein<br />ProPublica, May 13, 2011, 1:27 p.m<br /><br /><a href="http://www.propublica.org/article/cardiac-society-draws-bulk-of-funding-from-stent-makers">Link</a>Klempererhttp://www.blogger.com/profile/16734777579980886077noreply@blogger.com0tag:blogger.com,1999:blog-693673931660553312.post-7725727371476859602011-05-16T19:36:00.000+02:002011-05-16T19:39:00.617+02:00Many US medical associations and disease awareness groups depend heavily on funding by drug manufacturersBMJ 2011; 342:d2929 doi: 10.1136/bmj.d2929 (Published 10 May 2011)<br />Cite this as: BMJ 2011; 342:d2929<br /><br /> News<br /><br />Many US medical associations and disease awareness groups depend heavily on funding by drug manufacturers<br /><br /> Jeanne Lenzer<br /><br />+ Author Affiliations<br /><br /> 1New York<br /><br />Many medical societies and non-profit disease awareness organisations in the United States receive much of their funding from drug and device manufacturers, show documents recently released to the US senator Charles Grassley.<br /><br />Senator Grassley, a Republican of Iowa, asked for financial information in December 2009 from 33 professional associations and groups that conduct research or promote disease awareness.<br /><br />Among the organisations responding to Senator Grassley’s request was the American Medical Association, which reported that 16 drug, device, and communications companies donated nearly $5m (£3.1m; €3.5m) in 2007 for “continuing medical education” programmes and “communications conferences.”<br /><br />Large donations to the association included $499 000 from Takeda Pharmaceutical Company, which makes the blockbuster antidiabetes drug pioglitazone, to conduct a continuing medical education programme on diabetes. Teva Neuroscience, maker of rasagiline, a treatment for Parkinson’s disease, gave $450 000 for a programme on Parkinson’s disease; and Purdue Pharma, maker of OxyContin, a formulation of the painkiller oxycodone, donated $212 000 for a programme on pain management.<br /><br />The online investigative news organisation ProPublica (www.propublica.org), which scrutinised the documents received by Senator Grassley, says that manufacturers provided more than half of the total funding of the North American Spine Society in 2009, nearly half the funding of the Heart Rhythm Society in 2010, and more than 40% of the funding of the American Academy of Allergy, Asthma and Immunology in 2008.<br /><br />Many organisations issue professional recommendations and guidelines on drugs and devices manufactured by the companies that fund the organisation. For example, the Heart Rhythm Society issues guidelines on drugs, catheters, pacemakers, and implantable defibrillators used for rhythm disturbances. A ProPublica report says that the device manufacturers Medtronic, Boston Scientific, and St Jude Medical gave the society $4m in 2010. Twelve of the society’s 18 directors also received undisclosed amounts of funding from the companies.<br /><br />Senator Grassley told ProPublica, “If a group gets millions [of dollars] from a company that makes a product [prescribed] by its members, it is reasonable to wonder whether the guidance it offers on treatments would benefit that company.”<br /><br />ProPublica reported that Bruce Wilkoff, the incoming president of the Heart Rhythm Society, said, “We either get out of the business or we manage these relationships. That’s what we’ve chosen to do.”<br /><br />Jerome Hoffman, professor of emergency medicine at the University of Southern California in Los Angeles and an expert on industry influence in medicine, told the BMJ, “It’s unclear just what ‘business’ [Dr Wilkoff] is referring to, but the business of finding non-conflicted experts to write evidence based guidelines that serve the public in no way requires taking industry largesse.<br /><br />“The very notion of ‘managing’ such relationships is . . . self serving. We need to ask what purpose medical societies should serve, and if the answer has anything to do with promoting the public health we should insist that they stop, consciously or otherwise, serving a very separate master.”<br /><br />The American Medical Association did not respond to an inquiry by the BMJ regarding the reports.<br />Notes<br /><br />Cite this as: BMJ 2011;342:d2929Klempererhttp://www.blogger.com/profile/16734777579980886077noreply@blogger.com0tag:blogger.com,1999:blog-693673931660553312.post-5195020317656682702011-04-30T20:31:00.002+02:002011-04-30T20:36:13.787+02:00Interessenkonflikte bei Erstellern amerikanischer kardiologischer LeitlinienMendelson TB, Meltzer M, Campbell EG, Caplan AL, Kirkpatrick JN. <br />Conflicts of Interest in Cardiovascular Clinical Practice Guidelines. <br />Arch Intern Med 2011;171(6):577-84. (28.3.2011)<br /><a href="http://archinte.ama-assn.org/cgi/content/abstract/171/6/577">Abstract</a><br /><br />Beitrag im Forum Gesundheitspolitik: Amerikanische kardiologische Leitlinien: kann man ihnen vertrauen? <a href="http://forum-gesundheitspolitik.de/artikel/artikel.pl?artikel=1934">Link</a>Klempererhttp://www.blogger.com/profile/16734777579980886077noreply@blogger.com0tag:blogger.com,1999:blog-693673931660553312.post-55465606990250781312011-04-03T18:03:00.002+02:002011-04-03T18:07:38.708+02:00Lücken in der Transparenz: Meta-Analysen zumeist ohne Angaben von InteressenkonfliktenRoseman M, Milette K, Bero LA, Coyne JC, Lexchin J, Turner EH, et al. Reporting of Conflicts of Interest in Meta-analyses of Trials of Pharmacological Treatments. JAMA: The Journal of the American Medical Association 2011;305(10):10<br /><a href="http://jama.ama-assn.org/content/305/10/1008.abstract">Abstract</a> <br /><br />Lücken in der Transparenz: Meta-Analysen zumeist ohne Angaben von Interessenkonflikten <br />Beitrag im Forum Gesundheitspolitik <a href="http://forum-gesundheitspolitik.de/artikel/artikel.pl?artikel=1925">Link</a>Klempererhttp://www.blogger.com/profile/16734777579980886077noreply@blogger.com0tag:blogger.com,1999:blog-693673931660553312.post-27514741490560098782011-02-17T22:15:00.005+01:002011-02-17T22:26:37.141+01:00Knowledge of ghostwriting and financial conflicts-of-interest reduces the perceived credibility of biomedical research<span style="font-size:100%;">Die Offenlegung von Interessenkonflikten ist nicht nur theoretisch wichtig, sondern hat praktische Komsequenzen für die Verschreibungspraxis, denn sie trägt zur Skepsis bei. Das zeigt dieser kleine Versuch von Lacasse und Leo. Eine Schlussfolgerung der Autoren: "For industry [...] our results suggest that decreased disclosures are preferable" ist dann wohl auch eher als Warnung zu verstehen.</span><br /><br />While the impact of conflicts-of-interest (COI) is of increasing concern in academic medicine, there is little research on the reaction of practicing clinicians to the disclosure of such conflicts. We developed two research vignettes presenting a fictional antidepressant medication study, one in which the principal investigator had no COI and another in which there were multiple COI disclosed. We confirmed the face validity of the COI vignette through consultation with experts. Hospital-based clinicians were randomly assigned to read one of these two vignettes and then administered a credibility scale.<br /><br />Jeffrey R Lacasse, Jonathan Leo<br />Knowledge of ghostwriting and financial conflicts-of-interest reduces the perceived credibility of biomedical research<br />BMC Research Notes 2011, 4:27<br /><a href="http://www.biomedcentral.com/1756-0500/4/27">www.biomedcentral.com/1756-0500/4/27</a>JShttp://www.blogger.com/profile/07257719123362216476noreply@blogger.com0tag:blogger.com,1999:blog-693673931660553312.post-49745999460791060922011-02-17T22:01:00.006+01:002011-02-17T22:25:33.404+01:00The Inverse Benefit Law: How Drug Marketing Undermines Patient Safety and Public Health<!--[if gte mso 9]><xml> <w:worddocument> <w:view>Normal</w:View> <w:zoom>0</w:Zoom> <w:trackmoves/> <w:trackformatting/> <w:donotshowcomments/> <w:donotshowpropertychanges/> <w:hyphenationzone>21</w:HyphenationZone> <w:punctuationkerning/> <w:validateagainstschemas/> <w:saveifxmlinvalid>false</w:SaveIfXMLInvalid> <w:ignoremixedcontent>false</w:IgnoreMixedContent> <w:alwaysshowplaceholdertext>false</w:AlwaysShowPlaceholderText> <w:donotpromoteqf/> <w:lidthemeother>DE</w:LidThemeOther> <w:lidthemeasian>X-NONE</w:LidThemeAsian> <w:lidthemecomplexscript>X-NONE</w:LidThemeComplexScript> <w:compatibility> <w:breakwrappedtables/> <w:snaptogridincell/> <w:wraptextwithpunct/> <w:useasianbreakrules/> <w:dontgrowautofit/> <w:splitpgbreakandparamark/> <w:dontvertaligncellwithsp/> <w:dontbreakconstrainedforcedtables/> <w:dontvertalignintxbx/> <w:word11kerningpairs/> <w:cachedcolbalance/> </w:Compatibility> <w:browserlevel>MicrosoftInternetExplorer4</w:BrowserLevel> <m:mathpr> <m:mathfont val="Cambria Math"> <m:brkbin val="before"> <m:brkbinsub val="--"> <m:smallfrac val="off"> <m:dispdef/> <m:lmargin val="0"> <m:rmargin val="0"> <m:defjc val="centerGroup"> <m:wrapindent val="1440"> <m:intlim val="subSup"> <m:narylim val="undOvr"> </m:mathPr></w:WordDocument> </xml><![endif]--><!--[if gte mso 9]><xml> <w:latentstyles deflockedstate="false" defunhidewhenused="true" defsemihidden="true" defqformat="false" defpriority="99" latentstylecount="267"> <w:lsdexception locked="false" priority="0" semihidden="false" unhidewhenused="false" qformat="true" name="Normal"> <w:lsdexception locked="false" priority="9" semihidden="false" unhidewhenused="false" qformat="true" name="heading 1"> <w:lsdexception locked="false" priority="9" qformat="true" name="heading 2"> <w:lsdexception locked="false" priority="9" qformat="true" name="heading 3"> <w:lsdexception locked="false" priority="9" qformat="true" name="heading 4"> <w:lsdexception locked="false" priority="9" qformat="true" name="heading 5"> <w:lsdexception locked="false" priority="9" qformat="true" name="heading 6"> <w:lsdexception locked="false" priority="9" qformat="true" name="heading 7"> <w:lsdexception locked="false" priority="9" qformat="true" name="heading 8"> <w:lsdexception locked="false" priority="9" qformat="true" name="heading 9"> <w:lsdexception locked="false" priority="39" name="toc 1"> <w:lsdexception locked="false" priority="39" name="toc 2"> <w:lsdexception locked="false" priority="39" name="toc 3"> <w:lsdexception locked="false" priority="39" name="toc 4"> <w:lsdexception locked="false" priority="39" name="toc 5"> <w:lsdexception locked="false" priority="39" name="toc 6"> <w:lsdexception locked="false" priority="39" name="toc 7"> <w:lsdexception locked="false" priority="39" name="toc 8"> <w:lsdexception locked="false" priority="39" name="toc 9"> <w:lsdexception locked="false" priority="35" qformat="true" name="caption"> <w:lsdexception locked="false" priority="10" semihidden="false" unhidewhenused="false" qformat="true" name="Title"> <w:lsdexception locked="false" priority="1" name="Default Paragraph Font"> <w:lsdexception locked="false" priority="11" semihidden="false" unhidewhenused="false" qformat="true" name="Subtitle"> <w:lsdexception locked="false" priority="22" semihidden="false" unhidewhenused="false" qformat="true" name="Strong"> <w:lsdexception locked="false" priority="20" semihidden="false" unhidewhenused="false" qformat="true" name="Emphasis"> <w:lsdexception locked="false" priority="59" semihidden="false" unhidewhenused="false" name="Table Grid"> <w:lsdexception locked="false" unhidewhenused="false" name="Placeholder Text"> <w:lsdexception locked="false" priority="1" semihidden="false" unhidewhenused="false" qformat="true" name="No Spacing"> <w:lsdexception locked="false" priority="60" semihidden="false" unhidewhenused="false" name="Light Shading"> <w:lsdexception locked="false" priority="61" semihidden="false" unhidewhenused="false" name="Light List"> <w:lsdexception locked="false" priority="62" semihidden="false" unhidewhenused="false" name="Light Grid"> <w:lsdexception locked="false" priority="63" semihidden="false" unhidewhenused="false" name="Medium Shading 1"> <w:lsdexception locked="false" priority="64" semihidden="false" unhidewhenused="false" name="Medium Shading 2"> <w:lsdexception locked="false" priority="65" semihidden="false" unhidewhenused="false" name="Medium List 1"> <w:lsdexception locked="false" priority="66" semihidden="false" unhidewhenused="false" name="Medium List 2"> <w:lsdexception locked="false" priority="67" semihidden="false" unhidewhenused="false" name="Medium Grid 1"> <w:lsdexception locked="false" priority="68" semihidden="false" unhidewhenused="false" name="Medium Grid 2"> <w:lsdexception locked="false" priority="69" semihidden="false" unhidewhenused="false" name="Medium Grid 3"> <w:lsdexception locked="false" priority="70" semihidden="false" unhidewhenused="false" name="Dark List"> <w:lsdexception locked="false" priority="71" semihidden="false" unhidewhenused="false" name="Colorful Shading"> <w:lsdexception locked="false" priority="72" semihidden="false" unhidewhenused="false" name="Colorful List"> <w:lsdexception locked="false" priority="73" semihidden="false" unhidewhenused="false" name="Colorful Grid"> <w:lsdexception locked="false" priority="60" semihidden="false" unhidewhenused="false" name="Light Shading Accent 1"> <w:lsdexception locked="false" priority="61" semihidden="false" unhidewhenused="false" name="Light List Accent 1"> <w:lsdexception locked="false" priority="62" semihidden="false" unhidewhenused="false" name="Light Grid Accent 1"> <w:lsdexception locked="false" priority="63" semihidden="false" unhidewhenused="false" name="Medium Shading 1 Accent 1"> <w:lsdexception locked="false" priority="64" semihidden="false" unhidewhenused="false" name="Medium Shading 2 Accent 1"> <w:lsdexception locked="false" priority="65" semihidden="false" unhidewhenused="false" name="Medium List 1 Accent 1"> <w:lsdexception locked="false" unhidewhenused="false" name="Revision"> <w:lsdexception locked="false" priority="34" semihidden="false" unhidewhenused="false" qformat="true" name="List Paragraph"> <w:lsdexception locked="false" priority="29" semihidden="false" unhidewhenused="false" qformat="true" name="Quote"> <w:lsdexception locked="false" priority="30" semihidden="false" unhidewhenused="false" qformat="true" name="Intense Quote"> <w:lsdexception locked="false" priority="66" semihidden="false" unhidewhenused="false" name="Medium List 2 Accent 1"> <w:lsdexception locked="false" priority="67" semihidden="false" unhidewhenused="false" name="Medium Grid 1 Accent 1"> <w:lsdexception locked="false" priority="68" semihidden="false" unhidewhenused="false" name="Medium Grid 2 Accent 1"> <w:lsdexception locked="false" priority="69" semihidden="false" unhidewhenused="false" name="Medium Grid 3 Accent 1"> <w:lsdexception locked="false" priority="70" semihidden="false" unhidewhenused="false" name="Dark List Accent 1"> <w:lsdexception locked="false" priority="71" semihidden="false" unhidewhenused="false" name="Colorful Shading Accent 1"> <w:lsdexception locked="false" priority="72" semihidden="false" unhidewhenused="false" name="Colorful List Accent 1"> <w:lsdexception locked="false" priority="73" semihidden="false" unhidewhenused="false" name="Colorful Grid Accent 1"> <w:lsdexception locked="false" priority="60" semihidden="false" unhidewhenused="false" name="Light Shading Accent 2"> <w:lsdexception locked="false" priority="61" semihidden="false" unhidewhenused="false" name="Light List Accent 2"> <w:lsdexception locked="false" priority="62" semihidden="false" unhidewhenused="false" name="Light Grid Accent 2"> <w:lsdexception locked="false" priority="63" semihidden="false" unhidewhenused="false" name="Medium Shading 1 Accent 2"> <w:lsdexception locked="false" priority="64" semihidden="false" unhidewhenused="false" name="Medium Shading 2 Accent 2"> <w:lsdexception locked="false" priority="65" semihidden="false" unhidewhenused="false" name="Medium List 1 Accent 2"> <w:lsdexception locked="false" priority="66" semihidden="false" unhidewhenused="false" name="Medium List 2 Accent 2"> <w:lsdexception locked="false" priority="67" semihidden="false" unhidewhenused="false" name="Medium Grid 1 Accent 2"> <w:lsdexception locked="false" priority="68" semihidden="false" unhidewhenused="false" name="Medium Grid 2 Accent 2"> <w:lsdexception locked="false" priority="69" semihidden="false" unhidewhenused="false" name="Medium Grid 3 Accent 2"> <w:lsdexception locked="false" priority="70" semihidden="false" unhidewhenused="false" name="Dark List Accent 2"> <w:lsdexception locked="false" priority="71" semihidden="false" unhidewhenused="false" name="Colorful Shading Accent 2"> <w:lsdexception locked="false" priority="72" semihidden="false" unhidewhenused="false" name="Colorful List Accent 2"> <w:lsdexception locked="false" priority="73" semihidden="false" unhidewhenused="false" name="Colorful Grid Accent 2"> <w:lsdexception locked="false" priority="60" semihidden="false" unhidewhenused="false" name="Light Shading Accent 3"> <w:lsdexception locked="false" priority="61" semihidden="false" unhidewhenused="false" name="Light List Accent 3"> <w:lsdexception locked="false" priority="62" semihidden="false" unhidewhenused="false" name="Light Grid Accent 3"> <w:lsdexception locked="false" priority="63" semihidden="false" unhidewhenused="false" name="Medium Shading 1 Accent 3"> <w:lsdexception locked="false" priority="64" semihidden="false" unhidewhenused="false" name="Medium Shading 2 Accent 3"> <w:lsdexception locked="false" priority="65" semihidden="false" unhidewhenused="false" name="Medium List 1 Accent 3"> <w:lsdexception locked="false" priority="66" semihidden="false" unhidewhenused="false" name="Medium List 2 Accent 3"> <w:lsdexception locked="false" priority="67" semihidden="false" unhidewhenused="false" name="Medium Grid 1 Accent 3"> <w:lsdexception locked="false" priority="68" semihidden="false" unhidewhenused="false" name="Medium Grid 2 Accent 3"> <w:lsdexception locked="false" priority="69" semihidden="false" unhidewhenused="false" name="Medium Grid 3 Accent 3"> <w:lsdexception locked="false" priority="70" semihidden="false" unhidewhenused="false" name="Dark List Accent 3"> <w:lsdexception locked="false" priority="71" semihidden="false" unhidewhenused="false" name="Colorful Shading Accent 3"> <w:lsdexception locked="false" priority="72" semihidden="false" unhidewhenused="false" name="Colorful List Accent 3"> <w:lsdexception locked="false" priority="73" semihidden="false" unhidewhenused="false" name="Colorful Grid Accent 3"> <w:lsdexception locked="false" priority="60" semihidden="false" unhidewhenused="false" name="Light Shading Accent 4"> <w:lsdexception locked="false" priority="61" semihidden="false" unhidewhenused="false" name="Light List Accent 4"> <w:lsdexception locked="false" priority="62" semihidden="false" unhidewhenused="false" name="Light Grid Accent 4"> <w:lsdexception locked="false" priority="63" semihidden="false" unhidewhenused="false" name="Medium Shading 1 Accent 4"> <w:lsdexception locked="false" priority="64" semihidden="false" unhidewhenused="false" name="Medium Shading 2 Accent 4"> <w:lsdexception locked="false" priority="65" semihidden="false" unhidewhenused="false" name="Medium List 1 Accent 4"> <w:lsdexception locked="false" priority="66" semihidden="false" unhidewhenused="false" name="Medium List 2 Accent 4"> <w:lsdexception locked="false" priority="67" semihidden="false" unhidewhenused="false" name="Medium Grid 1 Accent 4"> <w:lsdexception locked="false" priority="68" semihidden="false" unhidewhenused="false" name="Medium Grid 2 Accent 4"> <w:lsdexception locked="false" priority="69" semihidden="false" unhidewhenused="false" name="Medium Grid 3 Accent 4"> <w:lsdexception locked="false" priority="70" semihidden="false" unhidewhenused="false" name="Dark List Accent 4"> <w:lsdexception locked="false" priority="71" semihidden="false" unhidewhenused="false" name="Colorful Shading Accent 4"> <w:lsdexception locked="false" priority="72" semihidden="false" unhidewhenused="false" name="Colorful List Accent 4"> <w:lsdexception locked="false" priority="73" semihidden="false" unhidewhenused="false" name="Colorful Grid Accent 4"> <w:lsdexception locked="false" priority="60" semihidden="false" unhidewhenused="false" name="Light Shading Accent 5"> <w:lsdexception locked="false" priority="61" semihidden="false" unhidewhenused="false" name="Light List Accent 5"> <w:lsdexception locked="false" priority="62" semihidden="false" unhidewhenused="false" name="Light Grid Accent 5"> <w:lsdexception locked="false" priority="63" semihidden="false" unhidewhenused="false" name="Medium Shading 1 Accent 5"> <w:lsdexception locked="false" priority="64" semihidden="false" unhidewhenused="false" name="Medium Shading 2 Accent 5"> <w:lsdexception locked="false" priority="65" semihidden="false" unhidewhenused="false" name="Medium List 1 Accent 5"> <w:lsdexception locked="false" priority="66" semihidden="false" unhidewhenused="false" name="Medium List 2 Accent 5"> <w:lsdexception locked="false" priority="67" semihidden="false" unhidewhenused="false" name="Medium Grid 1 Accent 5"> <w:lsdexception locked="false" priority="68" semihidden="false" unhidewhenused="false" name="Medium Grid 2 Accent 5"> <w:lsdexception locked="false" priority="69" semihidden="false" unhidewhenused="false" name="Medium Grid 3 Accent 5"> <w:lsdexception locked="false" priority="70" semihidden="false" unhidewhenused="false" name="Dark List Accent 5"> <w:lsdexception locked="false" priority="71" semihidden="false" unhidewhenused="false" name="Colorful Shading Accent 5"> <w:lsdexception locked="false" priority="72" semihidden="false" unhidewhenused="false" name="Colorful List Accent 5"> <w:lsdexception locked="false" priority="73" semihidden="false" unhidewhenused="false" name="Colorful Grid Accent 5"> <w:lsdexception locked="false" priority="60" semihidden="false" unhidewhenused="false" name="Light Shading Accent 6"> <w:lsdexception locked="false" priority="61" semihidden="false" unhidewhenused="false" name="Light List Accent 6"> <w:lsdexception locked="false" priority="62" semihidden="false" unhidewhenused="false" name="Light Grid Accent 6"> <w:lsdexception locked="false" priority="63" semihidden="false" unhidewhenused="false" name="Medium Shading 1 Accent 6"> <w:lsdexception locked="false" priority="64" semihidden="false" unhidewhenused="false" name="Medium Shading 2 Accent 6"> <w:lsdexception locked="false" priority="65" semihidden="false" unhidewhenused="false" name="Medium List 1 Accent 6"> <w:lsdexception locked="false" priority="66" semihidden="false" unhidewhenused="false" name="Medium List 2 Accent 6"> <w:lsdexception locked="false" priority="67" semihidden="false" unhidewhenused="false" name="Medium Grid 1 Accent 6"> <w:lsdexception locked="false" priority="68" semihidden="false" unhidewhenused="false" name="Medium Grid 2 Accent 6"> <w:lsdexception locked="false" priority="69" semihidden="false" unhidewhenused="false" name="Medium Grid 3 Accent 6"> <w:lsdexception locked="false" priority="70" semihidden="false" unhidewhenused="false" name="Dark List Accent 6"> <w:lsdexception locked="false" priority="71" semihidden="false" unhidewhenused="false" name="Colorful Shading Accent 6"> <w:lsdexception locked="false" priority="72" semihidden="false" unhidewhenused="false" name="Colorful List Accent 6"> <w:lsdexception locked="false" priority="73" semihidden="false" unhidewhenused="false" name="Colorful Grid Accent 6"> <w:lsdexception locked="false" priority="19" semihidden="false" unhidewhenused="false" qformat="true" name="Subtle Emphasis"> <w:lsdexception locked="false" priority="21" semihidden="false" unhidewhenused="false" qformat="true" name="Intense Emphasis"> <w:lsdexception locked="false" priority="31" semihidden="false" unhidewhenused="false" qformat="true" name="Subtle Reference"> <w:lsdexception locked="false" priority="32" semihidden="false" unhidewhenused="false" qformat="true" name="Intense Reference"> <w:lsdexception locked="false" priority="33" semihidden="false" unhidewhenused="false" qformat="true" name="Book Title"> <w:lsdexception locked="false" priority="37" name="Bibliography"> <w:lsdexception locked="false" priority="39" qformat="true" name="TOC Heading"> </w:LatentStyles> </xml><![endif]--><!--[if gte mso 10]> <style> /* Style Definitions */ table.MsoNormalTable {mso-style-name:"Normale Tabelle"; mso-tstyle-rowband-size:0; mso-tstyle-colband-size:0; mso-style-noshow:yes; mso-style-priority:99; mso-style-qformat:yes; mso-style-parent:""; mso-padding-alt:0cm 5.4pt 0cm 5.4pt; mso-para-margin:0cm; mso-para-margin-bottom:.0001pt; mso-pagination:widow-orphan; font-size:10.0pt; font-family:"Times","serif"; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-fareast-language:EN-US;} </style> <![endif]--><span style=";font-family:";font-size:12pt;" ><span style="font-size:100%;">Der Artikel, dessen Schwerpunkt die Ursachen irrationaler Verschreibung ist, weist besonders auf die Rolle von Interessenkonflikten bei der Erstellung von Leitlinien und deren Folgen hin.</span><br /><br />Recent highly publicized withdrawals of drugs from the market because of safety concerns raise the question of whether these events are random failures or part of a recurring pattern.<br />The inverse benefit law, inspired by Hart’s inverse care law, states that the ratio of benefits to harms among patients taking new drugs tends to vary inversely with how extensively the drugs are marketed. The law is manifested through 6 basic marketing strategies: reducing thresholds for diagnosing disease, relying on surrogate endpoints, exaggerating safety claims, exaggerating efficacy claims, creating new diseases, and encouraging unapproved uses.<br /><br />Howard Brody, MD, PhD, and Donald W. Light, PhD<br />The Inverse Benefit Law: How Drug Marketing Undermines Patient Safety and Public Health<br />Am J Public Health 2011<br /><a href="http://ajph.aphapublications.org/cgi/content/abstract/101/3/399">http://ajph.aphapublications.org/cgi/content/abstract/101/3/399</a><br /></span>JShttp://www.blogger.com/profile/07257719123362216476noreply@blogger.com0tag:blogger.com,1999:blog-693673931660553312.post-11861820486408738352011-01-14T08:10:00.000+01:002011-01-14T08:11:18.532+01:00"Interessenkonflikte sind etwas ganz Natürliches"Medizinprofessor fordert Professoren auf, ihre Nebeneinkünfte zu offenbaren<br />Deutschlandfunk 13.1.2011 <br /><a href="http://www.dradio.de/dlf/sendungen/campus/1364362/">Website</a> <br /><a href="javascript:popupAOD('http://www.dradio.de/aodflash/player.php?station=1&broadcast=9539&datum=20110113&playtime=1294926645&fileid=8f53cd49&sendung=9539&beitrag=1364362&/');">Audio on demand</a>Klempererhttp://www.blogger.com/profile/16734777579980886077noreply@blogger.com0tag:blogger.com,1999:blog-693673931660553312.post-29528927304817105772011-01-14T08:08:00.000+01:002011-01-14T08:09:24.232+01:00Gläserner ProfessorSpiegel online 3.1.2011 <a href="http://www.spiegel.de/unispiegel/jobundberuf/0,1518,736217,00.html">Link</a>Klempererhttp://www.blogger.com/profile/16734777579980886077noreply@blogger.com0tag:blogger.com,1999:blog-693673931660553312.post-50462012383878622662010-12-03T18:26:00.002+01:002010-12-03T18:32:47.062+01:00Government oversight agency calls on NIH to ban ghost-writing<div class="post-header"> </div> Das US-Project on Government Oversight hat die National Institutes of Health (NIH) <a href="http://www.pogo.org/pogo-files/letters/public-health/ph-iis-20101129.html">aufgefordert</a>, Forscher, die Artikel von anderen Ghostwriten lassen, von der Förderung auszuschließen. Die Forderung wird mit mehreren Beispielen unterlegt.<br /><br />Der einfachste Zugang und eine Reihe von interessanten Links in dem Blog von <a href="http://alison-bass.blogspot.com/2010/12/government-oversight-agency-calls-on.html">Alison Bass</a>:<br /><br />"Much has been written about the insidious practice of ghost-writing in medical research in <a href="http://alison-bass.blogspot.com/search?q=ghostwriting">this</a> and other blogs and news articles. Even Dr. Francis Collins, the director of the National Institutes of Health (NIH), expressed dismay over the problem in a C-SPAN interview last year, calling it a threat to the "integrity of science." So far, however, not much has been done to curb such abuses"JShttp://www.blogger.com/profile/07257719123362216476noreply@blogger.com0tag:blogger.com,1999:blog-693673931660553312.post-8194449287275194872010-11-09T12:37:00.000+01:002010-11-09T12:39:16.467+01:00Die öffentliche Reputation der Pharmaindustrie in den USA im Jahr 2009Annual RQ. 2009. Summary Report. A survey of the U.S. General pubic using the reputation quotient <br /><a href="http://www.harrisinteractive.com/vault/HI_BCC_Report_RQ_2009.pdf">Link</a><br /><br /><a href="http://forum-gesundheitspolitik.de/artikel/artikel.pl?artikel=1870">Beitrag</a> im Forum GesundheitspolitikKlempererhttp://www.blogger.com/profile/16734777579980886077noreply@blogger.com0tag:blogger.com,1999:blog-693673931660553312.post-61019502979966319182010-11-09T12:06:00.000+01:002010-11-09T12:07:37.154+01:00Physician Professionalismand Changes in Physician-Industry Relationships From 2004 to 2009. Arch Intern Med 2010;170(20):1820-26.<br />Campbell EG, Rao SR, DesRoches CM, Iezzoni LI, Vogeli C, Bolcic-Jankovic D, et al.<br /><a href="http://archinte.ama-assn.org/cgi/content/abstract/170/20/1820">Abstract</a>Klempererhttp://www.blogger.com/profile/16734777579980886077noreply@blogger.com0tag:blogger.com,1999:blog-693673931660553312.post-54522294742878329412010-11-07T22:38:00.001+01:002010-11-07T22:40:28.935+01:00Information from Pharmaceutical Companiesand the Quality, Quantity, and Cost of Physicians' Prescribing: A Systematic Review. <br />PLoS Medicine 19.10.2010 <a href="http://www.plosmedicine.org/article/info:doi/10.1371/journal.pmed.1000352">Link</a>Klempererhttp://www.blogger.com/profile/16734777579980886077noreply@blogger.com0tag:blogger.com,1999:blog-693673931660553312.post-6483151895296882792010-11-02T13:46:00.005+01:002010-11-02T13:53:51.154+01:00Richard Smith on editors’ conflicts of interestDer frühere Herausgeber des British Medical Journal schreibt in seinem Blog über Interessenkonflikte von Herausgebern. <a href="http://blogs.bmj.com/bmj/2010/11/02/richard-smith-on-editors-conflicts-of-interest/?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+bmj%2Fblogs+%28Latest+BMJ+blogs%29&q=w_bmj_podblog">Link</a><br /><br />Anlass ist der Beitrag im PLoS "Conflicts of Interest at Medical Journals". <a href="http://www.plosmedicine.org/article/info%3Adoi%2F10.1371%2Fjournal.pmed.1000354">Link</a>Klempererhttp://www.blogger.com/profile/16734777579980886077noreply@blogger.com0